CCM
BOLT icon

CAAS Capital Management’s Bolt Biotherapeutics BOLT Stock Holding History

CAAS Capital Management’s Portfolio BOLT Stock Details BOLT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-5,839
Closed -$173K – 781
2022
Q3 		$173K Buy
+5,839
New +$242K 0.01% 671
2021
Q2 		– Sell
-5,000
Closed -$3.29M – 1055
2021
Q1 		$3.29M Buy
+5,000
New +$3.25M 0.04% 457

Other funds holding BOLT

VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
PBPIA
Pivotal bioVenture Partners Investment Advisor San Francisco, California $280M AUM 181.4% 1-Year Est. Return
NFGH
Nan Fung Group Holdings Kai Tak, Hong Kong $121M AUM 56.89% 1-Year Est. Return
NM
Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BOTOTLSJU
Board of Trustees of The Leland Stanford Junior University Redwood City, California $849M AUM 55.45% 1-Year Est. Return

CAAS Capital Management's BOLT Position: Q4 2022 in Review

CAAS Capital Management sold out of Bolt Biotherapeutics (BOLT) in Q4 2022, closing a stake of 5,839 shares — an estimated $173K sold.

CAAS Capital Management first reported a position in BOLT in Q1 2021 and held it in 2 quarters. The position peaked at $3.29M in Q1 2021. 44 funds tracked by Wall St. Rank hold BOLT as of Q4 2022.

  • CAAS Capital Management reported no remaining Bolt Biotherapeutics position as of Q4 2022 after selling out during the quarter.
  • CAAS Capital Management sold 5,839 Bolt Biotherapeutics shares in Q4 2022, an estimated $173K.
  • CAAS Capital Management first reported a position in Bolt Biotherapeutics in Q1 2021 and held it in 2 quarters.
  • CAAS Capital Management's Bolt Biotherapeutics position peaked at $3.29M in Q1 2021.
  • 44 funds tracked by Wall St. Rank held Bolt Biotherapeutics as of Q4 2022.

Based on CAAS Capital Management's 13F filing for Q4 2022, filed 14 Feb 2023.